Cabaletta Bio's Rese-cel Shows Efficacy in Clinical Studies

TipRanks07:11 ET

Express News | Cabaletta Bio Announces Updated Clinical Data From First Patients Dosed With Rese-cel; Says 90% Of Patients Experienced Either No CRS Or Grade 1 CRS And 0-% Experienced No ICANS

Benzinga07:11 ET

Express News | Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses Across Multiple Indications With Rese-Cel at February Scientific Meetings

Reuters07:07 ET

Express News | Cabaletta Bio Announced Updated Data On Resecabtagene Autoleucel To Be Presented At 2025 Conferences; Covers Safety, Translational Data, Clinical Outcomes From First 10 Patients In RESET Program

BenzingaFeb 11 08:01 ET

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

GlobeNewswireFeb 11 08:00 ET

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

GlobeNewswireJan 29 08:00 ET